ALSUCRAL 200 Milligram Ireland - English - HPRA (Health Products Regulatory Authority)

alsucral 200 milligram

orion pharma a/s - sucralfate - 200 milligram

ALSUCRAL 500 Milligram Ireland - English - HPRA (Health Products Regulatory Authority)

alsucral 500 milligram

orion pharma a/s - sucralfate - 500 milligram

ALSUCRAL Tablets 200mg/ml Milligram Ireland - English - HPRA (Health Products Regulatory Authority)

alsucral tablets 200mg/ml milligram

orion pharma a/s - sucralfate - tablets - 200mg/ml milligram

ALSUCRAL 1 Ireland - English - HPRA (Health Products Regulatory Authority)

alsucral 1

orion pharma a/s - sucralfate - 1

ALSUCRAL 1 Ireland - English - HPRA (Health Products Regulatory Authority)

alsucral 1

orion pharma a/s - sucralfate - 1

Alsucral New Zealand - English - Medsafe (Medicines Safety Authority)

alsucral

pacific pharmaceuticals limited (part of mylan) - sucralfate 0.5 g - chewable tablet - 0.5 g - active: sucralfate 0.5 g

Alsucral (Pacific) New Zealand - English - Medsafe (Medicines Safety Authority)

alsucral (pacific)

pacific pharmaceuticals limited (part of mylan) - sucralfate - tablet - 0.5g, 1.0g - active: sucralfate

Alsucral Powder New Zealand - English - Medsafe (Medicines Safety Authority)

alsucral powder

pacific pharmaceuticals limited (part of mylan) - sucralfate 1 g - powder for oral solution - 1 g - active: sucralfate 1 g

Sucralfate Oral Suspension United States - English - NLM (National Library of Medicine)

sucralfate oral suspension

vistapharm, llc - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g in 10 ml - sucralfate oral suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer. sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

SUCRALFATE- sucralfate tablet United States - English - NLM (National Library of Medicine)

sucralfate- sucralfate tablet

pd-rx pharmaceuticals, inc. - sucralfate (unii: xx73205dh5) (sucralfate - unii:xx73205dh5) - sucralfate 1 g - sucralfate is indicated in: - short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.